ExploreWatchlistsPricing
  1. JP-listed companies
  3. Financials
  4. Income before tax

(219A)

Market cap
¥37.3B
P/E ratio
-17.3x
Heartseed develops regenerative heart muscle therapies using iPS cell-derived cardiac spheres to treat severe heart failure patients through medical institutions worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Dec 31, 2025289-58.19%
Oct 31, 2025691-184.43%
Oct 31, 2024-819-43.80%
Oct 31, 2023-1,457+3.28%
Oct 31, 2022-1,410+452.32%
Oct 31, 2021-255-73.68%
Oct 31, 2020-970+92.16%
Oct 31, 2019-505

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat